Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
"This new partnership agreement supports our financial guidance and reflects Alvotech's strong commitment to increasing patient access to more affordable healthcare," said Robert Wessman, Chairman and CEO of Alvotech.
The current multi-product commercialization partnership between Teva Pharmaceuticals and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the SIMLANDI brand in the U.S.
"This new partnership agreement supports our financial guidance and reflects Alvotech's strong commitment to increasing patient access to more affordable healthcare," said Robert Wessman, Chairman and CEO of Alvotech.
Alvotech董事長兼首席執行官羅伯特·韋斯曼表示：“這項新的合作協議支持了我們的財務指導，也反映了Alvotech對增加患者獲得更實惠的醫療保健機會的堅定承諾。”
The current multi-product commercialization partnership between Teva Pharmaceuticals and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the SIMLANDI brand in the U.S.
梯瓦製藥與Alvotech之間目前的多產品商業化合作夥伴關係保持不變，梯瓦將繼續在美國以SIMLANDI品牌將adalimumab-ryvk商業化。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧